About the Authors

Taku Suzuki

Contributed equally to this work with: Taku Suzuki, Katsunori Ikari, Koichiro Yano

Affiliations Institute of Rheumatology, Tokyo Women’s Medical University, Shinjuku, Tokyo, Japan, Department of Orthopaedic Surgery, Keio University School of Medicine, Shinjuku, Tokyo, Japan

Katsunori Ikari

Contributed equally to this work with: Taku Suzuki, Katsunori Ikari, Koichiro Yano

kikari@ior.twmu.ac.jp

Affiliation Institute of Rheumatology, Tokyo Women’s Medical University, Shinjuku, Tokyo, Japan

Koichiro Yano

Contributed equally to this work with: Taku Suzuki, Katsunori Ikari, Koichiro Yano

Affiliation Institute of Rheumatology, Tokyo Women’s Medical University, Shinjuku, Tokyo, Japan

Eisuke Inoue

Affiliation Institute of Rheumatology, Tokyo Women’s Medical University, Shinjuku, Tokyo, Japan

Yoshiaki Toyama

Affiliation Department of Orthopaedic Surgery, Keio University School of Medicine, Shinjuku, Tokyo, Japan

Atsuo Taniguchi

Affiliation Institute of Rheumatology, Tokyo Women’s Medical University, Shinjuku, Tokyo, Japan

Hisashi Yamanaka

Affiliation Institute of Rheumatology, Tokyo Women’s Medical University, Shinjuku, Tokyo, Japan

Shigeki Momohara

Affiliation Institute of Rheumatology, Tokyo Women’s Medical University, Shinjuku, Tokyo, Japan

Competing Interests

This work was supported by grants provided by the Japanese Ministry of Education, Culture, Sports, Science and Technology Grant-in-Aid for Scientific Research (KI), the Japanese Ministry of Health, Labour and Welfare (SM, HY) and the Japan Science and Technology Agency (HY). The IORRA cohort was supported by non-restricted research grants from commercial companies (Asahikasei Kuraray Medical Co., Ltd. Abbott Japan Co., Ltd. Asahikasei Pharma Corporation Astellas Pharma Inc. AstraZeneca K.K. Bristol-Myers Squibb Chugai Pharmaceutical Co., Ltd. Daiichi Fine Chemical Co., Ltd. Daiichi Sankyo Co., Ltd. Dainippon Sumitomo Pharma Co., Ltd. Dentsu, Sudler & Hennessey Inc. Eisai Co., Ltd. GlaxoSmithKline K.K. Hisamitsu Pharmaceutical Co.,Inc. Janssen Pharmaceutical K.K. Japan Tobacco Inc. Kaken Pharmaceutical Co., Ltd. Kissei Pharmaceutical Co., Ltd. Kowa Pharmaceutical Co., Ltd. Mitsubishi Chemical Medience Corporation Mitsubishi Tanabe Pharma Corporation Mochida Pharmaceutical Co., Ltd. MSD K.K., Mundipharma K.K. Nippon Chemiphar Co., Ltd. Nippon Shinyaku Co., Ltd. Novartis Pharma K.K. Otsuka Pharmaceutical Co., Ltd. Pfizer Japan Inc. Sanofi-Aventis K.K. Santen Pharmaceutical Co., Ltd. Sanwa Kagaku Kenkyusho Co., Ltd. Sekisui Medical Co., Ltd. Taishotoyama Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Teijin Pharma Limited Torii Pharmaceutical Co., Ltd. UCB Japan Co., Ltd. ZERIA Pharmaceutical Co., Ltd). However, these funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: KI. Performed the experiments: TS KI EI. Analyzed the data: TS KI KY EI. Contributed reagents/materials/analysis tools: KI KY YT AT HY SM. Wrote the paper: TS KI.